Table 4 List of differentially expressed proteins in validation phase.
Proteins | CAD (n = 253) | Control (n = 253) | RATIO | P -value | FUNCTION |
|---|---|---|---|---|---|
Adiponectin (ng/ml) | 6771.27 (5038.24–10976.64) | 8979.77 (6947.24–12666.71) | 0.75 | <0.0001 | It is a chemokine which enhances glucose utilization and fatty acid combustion. |
Apolipoprotein A-IV (μg/ml) | 32947.32 (26952.50–43190.75) | 41168.18 (33699.4–51181.45) | 0.800 | <0.0001 | A major component of HDL and potential activator of LCAT |
Apolipoprotein C-I (μg/ml) | 119.75 (87.25–159.53) | 144.99 (116.25–181.75) | 0.825 | <0.0001 | It has important role in the interface of fatty acid uptake and major inhibitor of cholesteryl ester transfer protein (CETP) |
Glutathione peroxidase 3 (ng/ml) | 13599.26 (7474.89–18502.31) | 16288.49 (10259.01–23961.43) | 0.834 | <0.0001 | Plays protective role in oxidative damage |
Peroxiredoxine-2 (ng/ml) | 19.54 (11.30–29.62) | 21.03 (13.68–84791.41) | 0.929 | 0.002 | It is involved in redox balance regulation; reduces peroxides via thioredoxin pathway |
Serum amyloid P-component (ng/ml) | 40855.06 (23281.44–69654.73) | 47680.4 (27776.45–84791.41) | 0.856 | 0.048 | It is a acute phase protein and may functions as a calcium-dependent lectin |
Albumin (g/dL) | 3.8 (3.50–4.1) | 4.3 (4.10–4.50) | 0.88 | <0.0001 | It is the major transporter protein in plasma and has role in reverse cholesterol transport |
Apolipoprotein A-I (mg/dL) | 90.89 (74.98–102.87) | 114.38 (101.14–130.31) | 0.794 | <0.0001 | Major player in the process of reverse cholesterol transport and promotes cholesterol efflux |
Apolipoprotein C-II (μg/ml) | 147.12 (63.78–253.50) | 129.18 (66.28–220.21) | 1.138 | 0.138 | Activator of lipoprotein lipase and a central player in lipoprotein metabolism |
PZP(ng/ml) | 46638.54 (22413.76–99311.91) | 48318.57 (25560.9–96970.9) | 0.965 | 0.384 | It is a proteinase inhibitor and also has endopeptidase inhibitor activity |
